Natera Unveils Data from Over 50,000 Patients Highlighting Signatera’s Power in Breast Cancer Detection

Reuters12-02

Natera Unveils Data from Over 50,000 Patients Highlighting Signatera's Power in Breast Cancer Detection

Natera Inc. has announced that at least twelve abstracts highlighting its Signatera™ test will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 9-12. The presentations will feature aggregated data from more than 50,000 patients across real-world evidence and prospective clinical studies. The data demonstrate the prognostic and predictive capabilities of Signatera in various breast cancer subtypes and clinical settings. Key findings to be presented include outcomes for patients with sustained minimal residual disease (MRD) negativity, the impact of ribociclib on ctDNA clearance in MRD-positive patients, and real-world adoption studies from leading institutions. Additionally, new data from the Signatera Genome study and several institution-based research projects will be shared during the symposium. The results are scheduled for presentation at SABCS and have not yet been publicly disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251202820466) on December 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588469053?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588469053","market":"us","top_or_hot":-1,"title":"Natera Unveils Data from Over 50,000 Patients Highlighting Signatera’s Power in Breast Cancer Detection","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Natera Unveils Data from Over 50,000 Patients Highlighting Signatera's Power in Breast Cancer Detection\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Natera Inc. has announced that at least twelve abstracts highlighting its Signatera™ test will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 9-12. The presentations will feature aggregated data from more than 50,000 patients across real-world evidence and prospective clinical studies. The data demonstrate the prognostic and predictive capabilities of Signatera in various breast cancer subtypes and clinical settings. Key findings to be presented include outcomes for patients with sustained minimal residual disease (MRD) negativity, the impact of ribociclib on ctDNA clearance in MRD-positive patients, and real-world adoption studies from leading institutions. Additionally, new data from the Signatera Genome study and several institution-based research projects will be shared during the symposium. The results are scheduled for presentation at SABCS and have not yet been publicly disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251202820466) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natera Unveils Data from Over 50,000 Patients Highlighting Signatera’s Power in Breast Cancer Detection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatera Unveils Data from Over 50,000 Patients Highlighting Signatera’s Power in Breast Cancer Detection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-02 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Natera Unveils Data from Over 50,000 Patients Highlighting Signatera's Power in Breast Cancer Detection\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Natera Inc. has announced that at least twelve abstracts highlighting its Signatera™ test will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 9-12. The presentations will feature aggregated data from more than 50,000 patients across real-world evidence and prospective clinical studies. The data demonstrate the prognostic and predictive capabilities of Signatera in various breast cancer subtypes and clinical settings. Key findings to be presented include outcomes for patients with sustained minimal residual disease (MRD) negativity, the impact of ribociclib on ctDNA clearance in MRD-positive patients, and real-world adoption studies from leading institutions. Additionally, new data from the Signatera Genome study and several institution-based research projects will be shared during the symposium. The results are scheduled for presentation at SABCS and have not yet been publicly disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251202820466) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1988902786.USD","symbol_name":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL27dCty:1","article_id":"2588469053","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588469053","pubTimestamp":1764680430,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Natera Inc. has announced that at least twelve abstracts highlighting its Signatera test will be presented at the 2025 San Antonio Breast Cancer Symposium , scheduled for December 9-12. The presentations will feature aggregated data from more than 50,000 patients across real-world evidence and prospective clinical studies. The data demonstrate the prognostic and predictive capabilities of Signatera in various breast cancer subtypes and clinical settings. Key findings to be presented include outcomes for patients with sustained minimal residual disease  negativity, the impact of ribociclib on ctDNA clearance in MRD-positive patients, and real-world adoption studies from leading institutions. Additionally, new data from the Signatera Genome study and several institution-based research projects will be shared during the symposium. The results are scheduled for presentation at SABCS and have not yet been publicly disclosed.Disclaimer: This news brief was created by Public Technologies  usi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","NTRA":"Natera, Inc.","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","BK4139":"生物科技","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC"},"translate_title":"Natera公布了来自50,000多名患者的数据，凸显了Signatera在乳腺癌检测方面的能力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":0.9},"content_text":"Natera Unveils Data from Over 50,000 Patients Highlighting Signatera's Power in Breast Cancer Detection\n    \n\n        Natera Inc. has announced that at least twelve abstracts highlighting its Signatera™ test will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 9-12. The presentations will feature aggregated data from more than 50,000 patients across real-world evidence and prospective clinical studies. The data demonstrate the prognostic and predictive capabilities of Signatera in various breast cancer subtypes and clinical settings. Key findings to be presented include outcomes for patients with sustained minimal residual disease (MRD) negativity, the impact of ribociclib on ctDNA clearance in MRD-positive patients, and real-world adoption studies from leading institutions. Additionally, new data from the Signatera Genome study and several institution-based research projects will be shared during the symposium. The results are scheduled for presentation at SABCS and have not yet been publicly disclosed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251202820466) on December 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588469053","isCrawlerRequest":true}